Company
LON:ONC
Oncimmune Holdings PLC is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The company has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
139 stories · page 5 of 7
Frontier IP Group (LON:FIPP) 65p £32.9m Frontier IP, a specialist in commercialising intellectual property, has raised its equity stake in portfolio company Celerum Limited from 10 per cent to 33.8 per cent.
The clinical advisory body said the EarlyCDT Lung test could bring a potential benefit of early treatment and improved outcomes, as well as reducing waiting times
Biodesix Inc “exceeded our expectations”, CEO Adam Hill said
The awards celebrate the extensive commercial relationships between the United Kingdom and Spain
Partner Biodesix will unveil EarlyCDT Lung to the American medical audience next month as part of a five-year agreement worth US$28mln
A study, led by Leeds University Academic Unit of Health Economics, said the EarlyCDT Lung test sped up the process of identifying the disease
The programme, brought together by the Oxford Centre for Early Cancer Detection, aims to understand how the liver changes while the tumour develops
In a note initiating the biotech firm with a price target of 150p, the broker forecast £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half
The new funds will be used to bankroll its commercial push based around its EarlyCDT technology, which is used to detect cancer
The biotechnology group said the deal, originally announced in June, will be worth up to US$28mln over the next five years
It has been a pivotal period for the cancer diagnostics specialist
The review is aiming to increase earlier cancer diagnosis among patients, something the company is trying to achieve with its EarlyCDT lung cancer test
They are Professor Tariq Sethi, Matthew Luttrell and Cléa Rosenfeld
As well as funding the push to take the EarlyCDT Lung device to market after a successful large-scale trial, the additional cash will also be used to fund research on other indications for the technology such as liver cancer
The diagnostics firm had presented its data at the World Conference for Lung Cancer in Barcelona
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Local distributor Sabartech has inked an agreement with Vithas Group, which operates 48 hospitals and medical centres
R-Pharm has the exclusive right to use EarlyCDT Lung in Russia for the next five years, and Oncimmune expects the partnership will generate revenues of at least £5mln
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
